Non-Clinical Pharmacokinetic/Pharmacodynamic and Early Clinical Studies Supporting Development of a Novel Subcutaneous Formulation for the Monoclonal Antibody Rituximab

Abstract

This overview article describes the non-clinical pharmacology, pharmacokinetic and clinical dose-finding programs supporting the development of a novel subcutaneous formulation for rituximab, a monoclonal antibody that selectively targets CD20-positive B-lymphocytes. The subcutaneous route of administration is expected to improve convenience for patients and to reduce healthcare professional resource use compared with conventional intravenous infusion. Various non-clinical and clinical studies were conducted to support the bridge from the approved intravenous formulation to the novel subcutaneous treatment. The underlying hypothesis for these studies was that achieving subcutaneous rituximab serum trough concentrations that are at least as high as those reached with the intravenous formulation would result in at least the same degree of receptor saturation. Preclinical mouse xenograft and cynomolgus monkey B-cell depletion studies were performed at intravenous and subcutaneous doses that were previously found to result in comparable serum concentrations in pharmacokinetic studies in the same species. Results from these non-clinical assessments guided dose selection for the subsequent phase 1b dose finding trials in patients with follicular lymphoma as part of maintenance treatment. A fixed dose of 1 400 mg was found to result in noninferior serum trough concentrations to the intravenous formulation. Clinical trials in the induction setting in patients with follicular lymphoma and chronic lymphocytic leukemia are currently ongoing.

Key words

clinical trials - dose finding - follicular lymphoma - intravenous - pharmacology - preclinical studies

• References

• 1 Maloney DG, Grillo-López AJ, White CA et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 1997; 90: 2188-2195
• 2 Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs 2003; 63: 803-843
• 3 Coiffier B, Lepage E, Brière J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242
• 4 Shivakumar SP, Anderson DR, Couban S. Catheter-associated thrombosis in patients with malignancy. J Clin Oncol 2009; 27: 4858-4864
• 5 Barber ND, Hoffmeyer UK. Comparison of the cost-effectiveness of administering heparin subcutaneously or intravenously for the treatment of deep vein thrombosis. Ann R Coll Surg Engl 1993; 75: 430-433
• 6 Pivot X, Gligorov J, Muller V et al. Patient preference for subcutaneous versus intravenous adjuvant trastuzumab: results of the PREFHER study. The Breast 2013; 22 (Suppl. 01) S87 (Abstract 207)
• 7 Bittner B, Richter WF, Hourcade-Potelleret F et al. Development of a subcutaneous formulation for trastuzumab – nonclinical and clinical bridging approach to the approved intravenous dosing regimen. Arzneimittelforschung 2012; 62: 401-409
• 8 Wynne C, Harvey V, Schwabe C et al. Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J Clin Pharmacol 2012; [epub ahead of print] DOI: 10.1177/0091270012436560.
• 9 Ismael G, Hegg R, Muehlbauer S et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicenter, randomized trial. Lancet Oncol 2012; 13: 869-878
• 10 MabThera™ (rituximab) summary of product characteristics 2009 Available from http://www.mabthera.com/portal/mabthera/safety_information
• 11 Dani B, Platz R, Tzannis ST. High concentration formulation feasibility of human immunoglobulin G for subcutaneous administration. J Pharm Sci 2007; 96: 1504-1517
• 12 Shire SJ, Shahrokh Z, Liu J. Challenges in the development of high protein concentration formulations. J Pharm Sci 2004; 93: 1390-1402
• 13 Frost GI. Recombinant human hyaluronidase (rHuPH20): An enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 2007; 4: 427-440
• 14 By Adler M, Mahler H-C, Stauch OB. Highly concentrated pharmaceutical formulations. Patent application submitted in the European Union (Patent application number: 20110076273). Available at: http://www.faqs.org/patents/app/20110076273
• 15 Zheng Y, Tesar DB, Benincosa L et al. Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration. MAbs 2012; 4: 243-255
• 16 Yocum RC, Vaughn DE, Mongiovi DJ et al. Clinical trial of recombinant human PH20 hyaluronidase’s effect on subcutaneous absorption and pharmacokinetics of a large protein molecule therapeutic. Proceedings of the 34^th Annual Meeting and Exposition of the Controlled Release Society 2007, held 7–11 July 2007, Long Beach, California
• 17 Mao CP, Brovarney MR, Dabbagh K et al. Subcutaneous versus intravenous administration of rituximab: Pharmacokinetics, CD20 target coverage and B-cell depletion in Cynomolgus monkeys. PlosOne [accepted]
• 18 Tucker CA, Bebb G, Klasa RJ et al. Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma. Leuk Res 2006; 30: 449-457
• 19 Ng CM, Lum BL, Gimenez V et al. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res 2006; 23: 1275-1284
• 20 Wang DD, Zhang S, Zhao H et al. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol 2009; 49: 1012-1024
• 21 Salar A, Bouabdallah R, McIntyre C et al. A two-stage phase Ib study to investigate the pharmacokinetics, safety and tolerability of subcutaneous rituximab in follicular lymphoma as part of maintenance treatment. Blood 2010; 116 (Abstract 2858)
• 22 Salar A, Avivi I, Larouche JF et al. Final results of the BP22333 study demonstrate non-inferior pharmacokinetics and safety of subcutaneous administration of rituximab compared with intravenous administration as maintenance therapy in patients with follicular lymphoma. Blood 2012; 120 (Abstract 1641)
• 23 Davies A, Merli F, Mihaljevic B et al. Pharmacokinetics (PK), safety and overall response rate (ORR) achieved with subcutaneous (SC) administration of rituximab in combination with chemotherapy were comparable to those achieved with intravenous (IV) administration in patients (pts) with follicular lymphoma (FL) in the first-line setting: stage 1 results of the phase III SABRINA study (BO22334). Blood 2012; 120 (Abstract 1629)